keyword
https://read.qxmd.com/read/21480952/reversible-posterior-leucoencephalopathy-syndrome-in-an-elderly-male-on-sunitinib-therapy
#21
REVIEW
Biswa M Padhy, Saravana P Shanmugam, Yogendra K Gupta, Aman Goyal
AIMS: Reversible posterior leucoencephalopathy syndrome (RPLS) has been reported following the use of anti-vascular endothelial growth factor (VEGF) agents such as bevacizumab, sorafinib and sunitinib. In this report we present a case of RPLS that occurred in an elderly male on sunitinib therapy. METHODS: Other case reports of sunitinib-induced RPLS were reviewed and causality assessment was carried out using the World Health Organization-Uppsala Monitoring Centre criteria and the Naranjo algorithm...
May 2011: British Journal of Clinical Pharmacology
https://read.qxmd.com/read/21249514/sorafenib-versus-cytotoxic-chemotherapy-for-patients-with-advanced-hepatocellular-carcinoma-a-retrospective-single-institution-study
#22
COMPARATIVE STUDY
Soohyeon Lee, Sang Hyun Yoon, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Hye Jin Choi
BACKGROUND: Prior to the 2008 advent of sorafenib, traditional cytotoxic agents were the therapeutic mainstay for patients with advanced hepatocellular carcinoma (HCC). We thus undertook a clinical study of sorafinib and conventional cytotoxic therapy for HCC, comparing efficacy and safety. METHODS: From January, 2002 to December, 2009, 173 patients with unresectable HCC were reviewed retrospectively. Among them, 44 (25.4%) had been treated with sorafenib, and the remainder had received cytotoxic therapy (CTX)...
June 2012: Investigational New Drugs
https://read.qxmd.com/read/19299115/-potential-role-of-antiangiogenic-treatment-in-neuroblastoma
#23
REVIEW
M Taylor, B Geoerger, J Lagodny, F Farace, G Vassal, J Rössler
Focus on new drug development over the last few years has yielded new agents that differ from unspecific classical chemotherapeutics and ionizing radiation, while still targeting the cancer cell itself. Antiangiogenesis is a totally distinct approach targeting the tumor's blood vessels. This concept has now found its eligibility for the treatment of several adult solid tumors: the human antivascular endothelial growth factor (VEGF) antibody bevacizumab, as well as the VEGF receptor tyrosine kinase inhibitors, sunitinib and sorafinib, have recently been licensed by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) for the treatment of colorectal, renal, and lung cancer...
May 2009: Archives de Pédiatrie: Organe Officiel de la Sociéte Française de Pédiatrie
https://read.qxmd.com/read/19299048/-targeted-therapies-and-their-indications-in-solid-neoplasias
#24
REVIEW
C Dreyer, E Raymond, S Faivre
Targeted therapies are widely used in cancer because of their effectiveness, even in tumours that are resistant to conventional chemotherapy such as kidney or hepatocellular carcinomas. There are different families classified according to their mode of action. The antiangiogenics block tumor angiogenesis by acting on VEGF or its receptor. The main molecules are bevacizumab, sunitinib, and sorafinib. HER inhibitors work by blocking these receptors, which control different signaling intracellular pathways, and include an inhibitor of HER2, trastuzumab, and various inhibitors of HER1, or EGFR, including cetuximab, erlotinib, and gefitinib...
May 2009: La Revue de Médecine Interne
https://read.qxmd.com/read/17852116/antitumor-necrosis-factor-tnf-a-antibodies-in-the-treatment-of-renal-cell-cancer
#25
JOURNAL ARTICLE
Nick Maisey
The kinase inhibitors sorafinib and sunitinib have demonstrated significant activity in renal cell carcinoma (RCC), and are now approved by the FDA for use in advanced disease. There still remains a need for novel therapies. Our group were the first to demonstrate activity of thalidomide in RCC, believed to be in part related to the modulation of tumor necrosis factor (TNF-a), a cytokine secreted by RCC with a number of tumor promoting properties. We subsequently conducted a phase II trial of the TNF-a monoclonal antibody infliximab in patients with previously treated advanced RCC...
2007: Cancer Investigation
https://read.qxmd.com/read/17460422/do-the-results-of-the-new-trials-change-the-standard-treatment-of-metastatic-renal-cell-cancer
#26
JOURNAL ARTICLE
Sasja F Mulder, Dick Johan van Spronsen, Pieter H M De Mulder
With the emergence of novel angiogenesis inhibitors, we are moving to a new era for patients with metastasized renal cell carcinoma. Since the results achieved reflect more a modification of the natural course of the disease than a cure, past achievements should not be neglected. Low-risk patients with clear cell histology, especially those with pulmonary metastasis only, should still be offered cytokine therapy. For intermediate-risk patients sunitinib is the treatment of choice. For high-risk patients, temsirolimus has to date provided the most convincing data, its availability is however limited...
May 2007: Onkologie
https://read.qxmd.com/read/17341847/rap1-b-raf-signaling-is-activated-in-neuroendocrine-tumors-of-the-digestive-tract-and-raf-kinase-inhibition-constitutes-a-putative-therapeutic-target
#27
JOURNAL ARTICLE
Dorothee Karhoff, Susanne Sauer, Jörg Schrader, Rudolf Arnold, Volker Fendrich, Detlef K Bartsch, Dieter Hörsch
OBJECTIVE: Molecular pathogenesis of digestive neuroendocrine tumors (dNETs) is largely unknown. Recently, the serine-threonine kinase B-Raf was identified as an oncogene in endocrine cancer such as thyroid carcinoma. In endocrine cells, the small G-protein Rap1 stimulates mitogen-activated protein kinase (MAPK) signaling by activating B-Raf. We examined the expression of Rap1 and B-Raf in dNETs and their contribution to MAPK signaling in neuroendocrine cell lines. In addition, we explored the effect of suppressing B-Raf kinase by the recently developed inhibitor BAY43-9006 (Sorafinib) on growth, apoptosis and MAPK activation neuroendocrine cell lines...
2007: Neuroendocrinology
1
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.